Abstract 374P
Background
Oral lichen planus (OLP) is an autoimmune disorder that causes a persistent inflammatory condition that affects the oral mucosa. The precise cause of OLP is unknown, however it is thought to be a combination of genetic predisposition, environmental factors, and immunological dysregulation. Oral lichen planus is classified as a potentially oral malignant lesion (POML) because it has the potential to develop into oral squamous cell cancer (OSCC).
Methods
34 individuals with OLP were followed for three years in this prospective clinic-histologic investigation. Tissue samples from these patients were immunohistochemically and histomorphometrically examined for CD34 and CD105 (Endoglin). The patients received routine oral preventive therapy at three-month intervals and were followed for up to three years. The possibility for a malignant transformation was evaluated clinically, and in the event of clinical suspicion, a repeat biopsy was undertaken to rule out malignancy.
Results
The clinical and histological parameters were analyzed using the paired 't' test with the assumption of normal distribution and with an appropriate sample size of 34. During the three-year follow-up period, 73% (n=25/34) of the total patients never developed oral cancer. OSCC was the most typically found, with the Gingivo-Buccal Sulcus area being the most prevalent site. The mean Vascular Caliber (VC) utilizing CD 34 and CD 105 (μm2) in PMOL was 8.5 ± 2.0 μm2 and 5.4 ± 1.2 μm2, respectively. The mean VC - CD 34 and CD105 did differ statistically (p-value<0.05). It has been reported that patients with 'erosive' OLP had a higher malignant transformation potential (n=09/34) and higher levels of CD34 and CD105 than patients without malignant transformation (p-value<0.01).
Conclusions
CD 34 and CD105 markers were found to be beneficial in predicting the malignant transformation potential of Erosive OLP when utilized in evaluating micro vessel density and vessel morphometry. This suggests that CD34 and CD105 may be useful immunohistological indicators for assessing the early stage of malignant transformation potential in POMLs, particularly OLP, well before 3.0 years. As a result, CD34 and Endoglin are being recommended as IHC Panel Markers for determining OLP prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract